4/A: Elite Pharmaceuticals CEO Amends Filing to Correct Direct Holdings
SEC Filing
Nasrat Hakim, CEO of Elite Pharmaceuticals, files an amended Form 4 to correct previously reported direct holdings of common stock.
Summary
- Nasrat Hakim, CEO and President of Elite Pharmaceuticals, filed an amended Form 4 on April 2, 2024, to correct an error in the direct holdings of common stock previously reported on December 29, 2023.
- The amendment clarifies the reporting person's direct holdings of common stock.
Sentiment
Score: 7
Explanation: The document is a routine correction of a previous filing, indicating a neutral sentiment. The correction itself doesn't suggest any underlying issues, but highlights the importance of accurate reporting.
Negatives
- The original Form 4 filing contained an error regarding the direct holdings of common stock.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, ensuring transparency in the market.
Stakeholder Impact
- Accurate reporting of insider holdings is important for maintaining investor confidence.
Key Dates
| Date | Description |
|---|---|
| 12/29/2023 | Date of the original Form 4 filing with incorrect direct holdings. |
| 04/02/2024 | Date of the amended Form 4 filing to correct direct holdings. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.